Ipsos Healthcare adds Hidradenitis Suppurativa (HS) to Global Therapy Monitor Portfolio

Ipsos Healthcare, the global healthcare division of Ipsos, has launched the Hidradenitis Suppurativa (HS) Therapy Monitor in the EU5. The HS Monitor, part of Ipsos’ Autoimmune Real World Evidence portfolio, launched in the EU5 in Q2 of 2017, with plans to extend to other markets.

Ipsos Healthcare adds Hidradenitis Suppurativa (HS) to Global Therapy Monitor Portfolio

The new syndicated study will combine real world evidence on the treatment of HS patients with treating doctors’ perceptions, providing a comprehensive understanding of the HS landscape in the EU5. Subscribers to the Monitor will be able to examine and size the HS market in each country (including the biologic market), understand HS patient journeys, gauge doctors’ perceptions of products used to treat HS, assess their treatment approaches, and much more.

The HS Therapy Monitor extends Ipsos’ Autoimmune RWE portfolio, which also includes Rheumatoid Arthritis, Spondyloarthropathies, Crohn’s Disease, Ulcerative Colitis, Psoriasis and Multiple Sclerosis diseases.

More insights about Health

Consumer & Shopper